Calculate your SIP ReturnsExplore


Days Range

Data is not available currently. Please check back later.

Data is not available currently. Please check back later.

About Lupin

Lupin Ltd is involved in the business of manufacturing pharmaceuticals. The company was founded in 1968. Lupin Laboratories Pvt. Ltd. was incorporated in 1972. It commissioned the first formulations plant and R&D Centre at Aurangabad in 1979. Lupin received US FDA approvals for the Ankleshwar and Mandideep plants in 1989. The company was listed on an exchange in 1993 after an IPO. In 2000, the company received US FDA approval for the Cefotaxime facility at Mandideep. Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd., and as a result, Lupin Ltd was formed in 2001. After 2 years (2003), it incorporated Lupin Pharmaceuticals Inc. USA for trading, marketing and developmental activities in the US. In 2007, the company acquired Rubamin Laboratories Ltd., Vadodara and renamed it Novodigm Ltd. It became the 5th largest generic player in the US in 2010. Post 2 years, the company entered the NIFTY 50 Index in 2012. The company finished the acquisition of Symbiomix Therapeutics, LLC, New Jersey, U.S., in 2017. It launched Atharv Ability – State-of-the-Art, Multi-Disciplinary Neuro Rehabilitation Center in Mumbai in 2023. Lupin’s Supply Chain Team won the award for ‘Best-in-Class Supply Chain Strategy’ at the 15th ELSC Leadership Awards in 2023.

Business Segments

  • Key Therapeutic Areas: The company offers an expansive portfolio of products under this segment. Through this segment, it enjoys a  substantial market share in therapies such as cardiovascular, respiratory, diabetes, neurology, gastrointestinal and women’s health.
  • Generics: The company’s generic business is ranked #6 in the Indian Pharmaceutical Market (IPM). It possesses a significant presence in CNS, gynaecology, pain management and vitamin-mineral supplements, among others.  
  • Biosimilars: The company runs this segment through Lupin Biotech, which manufactures high-quality biologics that are accessible and affordable for patients globally. Products under this segment include Filgrastim and Peg-Filgrastim, and Etanercept.
  • Specialty: The specialty business of the company is supported by strong research and manufacturing capabilities. The specialty products under this segment include Solosec in the US and NaMuscla in Europe.
  • Over-the-Counter (OTC): Under this segment, the company produces drugs, which are considered the first line of defence against non-serious ailments. A few of the products under this segment include LupinLife, Softovac, Lupizyme, etc.
  • Active Pharmaceutical Ingredients (API): The company is a leading API manufacturer in India. It supplies to more than 70 countries around the globe.
  • Global Institutional Business (GIB): This segment provides high-quality, affordable, and reliable medicines to underserved communities, enabling a healthy and disease-free life. The company has evolved into a comprehensive solution for all anti-TB medications.
  • Tech-Driven Offerings: The company provides tech-enabled products such as Bluetooth-enabled inhalation devices or an AI-driven chatbot to answer queries about key therapies.


As of March 31, 2023, the company had 28 subsidiaries and a few of them are listed below:
  • Lupin Pharmaceuticals, Inc., USA: It is a wholly owned subsidiary of Lupin Ltd, which was incorporated on June 30, 2003. It manufactures, markets and/or distributes more than 181 drugs in the United States.
  • Pharma Dynamics (Proprietary) Limited, South Africa: This is a wholly-owned subsidiary of the company, which is one of the largest generic medicine providers in South Africa.

Key Personnel

Nilesh D Gupta, Managing Director Nilesh D Gupta is currently the MD of Lupin. He joined the company in 2002 and is responsible for its research, supply chain, manufacturing, quality, and regulatory operations. Mr Gupta has been involved in developing and executing the company’s core strategy, which has helped it emerge as a global leader in the generics space and in India.

Management Outlook

  • The company believes that its India business has a very positive outlook and is well poised to achieve sustainable growth. Lupin is actively working on various initiatives to enhance its performance, which include focusing on business imperatives, process improvement, and engaging with stakeholders such as doctors, patients, distribution channels, and consumers. 
  • The company is in a decent position to achieve new milestones and contribute to a brighter future by leveraging its brand-building capabilities, enhanced manpower and robust portfolio of products and by targeting depth into specific therapeutic segments.

Parent Organisation
Indian Private
Managing Director
M D Gupta
NSE Symbol

Peer Comparision

StocksLTP (₹)Market Cap (cr)52 Week Low-High (₹)

Community Discussion

22th April 2024
Lupin Gets A Green Light From US-FDA: Know What The Product Is and What Market Think? Lupin stock soared to 3.5% as the pharmaceutical company got approval from the Food and Drug Administration (US FDA) for the launch of a drug in the United States. The Pharmaceutical major has announced the launch of Mirabegron Extended-release tablets of 25mg in The United States Market, The company has said that they have introduced this medication after receiving approval from the US Food and Drug Administration. What are Mirabegron Extended-Release Tablets? Mirabegron is a medication which helps in treating an overactive bladder and wetting accidents. Mirabegron Extended-Release tablet is a generic equivalent of Myrbetriq Extended-Release tablets of Astellas Pharma Global Development, Inc. The tablets are a medication used to treat overactive bladder (OAB) symptoms, such as frequent or urgent urination and urinary incontinence. This medication works by relaxing a certain bladder muscle called a detrusor. About Lupin Ltd The pharma major, Headquartered in Mumbai manufactures and sells a variety of branded and generic medications, as well as Active Pharmaceutical Ingredients (APIs). In the US, Lupin ranks as the third-largest pharmaceutical company by prescriptions. In FY23, Lupin invested around 8% of its revenue in research and development. Lupin has 15 manufacturing sites and 7 research centres globally, with a workforce of over 20,000 professionals. The Company has its products available in more than 100 markets, including the US, India, South Africa, and regions across Asia Pacific (APAC), Latin America, Europe, and the Middle East. Lupin focuses on cardiovascular, anti-diabetic, and respiratory medications and also operates in areas like anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health. Market of Mirabegron Extended-Release Tablets in The United States The Mirabegron Extended-Release tablets had estimated annual sales of $1,019 million in the US (according to IQVIA MAT February 2024), which means around Rs.8500 crores. With approval from FDA Lupin will now be entering this market with their medicine. How Has The Market Reacted? The shares of Lupin surged around 3.5% on Monday, 22nd April trading at Rs.1600 after this news, The markets have reacted positively to the company launching a new medicine in the US market, The stock has given an attractive multi-bagger return of around 128% in the past 1 year and has made a 52 week of Rs.1704.25. Conclusion After launching in the US market and getting approval from the FDA, Lupin is set to enter the US market for Mirabegron Extended Release Tablets and this will also give a rise in revenues for the pharma company ahead. Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions. Angel One Lupin Share Price Today - Buy/Sell Lupin Stock Live NSE,BSE | Angel One Lupin Share Price - Get Lupin LIVE BSE/NSE Stock price with latest research reports, balance sheet, Fundamental Analysis and share price history of Lupin at Angel One.
0 Replies

Lupin Ltd FAQs

Lupin Ltd (LUPIN) share price as of July 18, 2024, on NSE is Rs 1817.25 (NSE) and Rs 1817.25 (BSE) on BSE.
Yes, You can buy Lupin Ltd (LUPIN) shares by opening a Demat account with Angel One.
Lupin Ltd (LUPIN) share can be bought through the following modes:
1. Direct investment: You can buy Lupin Ltd (LUPIN) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Lupin Ltd (LUPIN) shares.
Open Free Demat Account!

Enjoy Zero Brokerage on Equity Delivery

Join our 2 Cr+ happy customers

Top Stocks

VIEW ALLView All Stocks

Top Gainers

VIEW ALLView All Stocks

Top Losers

VIEW ALLView All Stocks

Enjoy Zero Brokerage on Equity Delivery
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link
Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.